We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+12.76%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.18B
AUM Growth
-$420M
Cap. Flow
-$342M
Cap. Flow %
-15.71%
Top 10 Hldgs %
69.34%
Holding
52
New
10
Increased
7
Reduced
16
Closed
7

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$19.8M
2
AMRN
Amarin Corp
AMRN
+$15.3M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$13.5M
4
ESTA icon
Establishment Labs
ESTA
+$12.2M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$7.88M

Top Sells

Rank Stock Value
1
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$71.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$69M
3
PTCT icon
PTC Therapeutics
PTCT
+$66.7M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$48.4M
5
PCRX icon
Pacira BioSciences
PCRX
+$45.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CARM
26
DELISTED
Carisma Therapeutics
CARM
$14.6M 0.67%
340,000
– –
INDP icon
27
Indaptus Therapeutics
INDP
$175M
$14.5M 0.67%
1,148
– –
ESTA icon
28
Establishment Labs
ESTA
$2.73B
$11.4M 0.53%
+475,000
New +$12.2M
GBT
29
DELISTED
Global Blood Therapeutics, Inc.
GBT
$10.9M 0.5%
287,500
-413,048
-59% -$18.3M
VNDA icon
30
Vanda Pharmaceuticals
VNDA
$315M
$9.87M 0.45%
430,000
-2,370,191
-85% -$48.4M
ACER
31
DELISTED
Acer Therapeutics Inc
ACER
$8.63M 0.4%
+280,000
New +$7.5M
FENC icon
32
Fennec Pharmaceuticals
FENC
$333M
$8.39M 0.39%
1,022,666
– –
YMAB
33
DELISTED
Y-mAbs Therapeutics
YMAB
$8.23M 0.38%
+310,000
New +$7.88M
CRSP icon
34
CRISPR Therapeutics
CRSP
$4.88B
$6.54M 0.3%
+147,368
New +$7.72M
ALIM
35
DELISTED
Alimera Sciences
ALIM
$6.12M 0.28%
416,105
– –
TSRO
36
DELISTED
TESARO, Inc.
TSRO
$5.85M 0.27%
+150,000
New +$5.3M
PRNB
37
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$2.19M 0.1%
+75,000
New +$2.12M
ACAD icon
38
Acadia Pharmaceuticals
ACAD
$4.39B
$2.08M 0.1%
+100,000
New +$1.57M
DBVT
39
DBV Technologies
DBVT
$804M
$1.21M 0.06%
+5,400
New +$1.1M
XBI icon
40
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$1.18M 0.05%
1,500,000
-250,000
-14% -$24.2M
ONCS
41
DELISTED
OncoSec Medical Incorporated
ONCS
$700K 0.03%
2,273
-15,944
-88% -$4.9M
OTLK icon
42
Outlook Therapeutics
OTLK
$171M
$670K 0.03%
4,272
– –
QQQ icon
43
PUT
Invesco QQQ Trust
QQQ
$469B
$175K 0.01%
+500,000
New +$90.5M
ONSIW
44
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$3K ﹤0.01%
233,333
– –
ALNY icon
45
Alnylam Pharmaceuticals
ALNY
$29.5B
– –
-700,100
Closed -$69M
VKTX icon
46
Viking Therapeutics
VKTX
$3.8B
– –
-4,471,300
Closed -$42.4M
TECX
47
Tectonic Therapeutic
TECX
$527M
– –
-8,333
Closed -$2.86M
CBAY
48
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,282,374
Closed -$17.2M
SPPI
49
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-3,419,818
Closed -$71.7M
DERM
50
DELISTED
Dermira, Inc.
DERM
– –
-1,841,823
Closed -$16.9M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Avoro Capital Advisors held 52 positions worth $2.18B, down 16% from $2.6B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors withdrew a net $342M in Q3 2018, closing 7 positions and reducing 16 holdings. Its most notable exit was Spectrum Pharmaceuticals Inc, an estimated $71.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Amarin Corp worth $65.8M.

  • Avoro Capital Advisors's largest Q3 2018 buy was Amarin Corp: 202,250 shares worth $65.8M.
  • Avoro Capital Advisors added most to Tricida, Inc. Common Stock in Q3 2018, an estimated $19.8M increase.
  • Avoro Capital Advisors's biggest Q3 2018 reduction was PTC Therapeutics, cutting an estimated $66.7M.
  • Avoro Capital Advisors fully exited Spectrum Pharmaceuticals Inc in Q3 2018, selling an estimated $71.7M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $2.18B portfolio in Q3 2018.
  • Avoro Capital Advisors opened 10 new positions and closed 7 in Q3 2018.
  • Avoro Capital Advisors's portfolio value fell 16% quarter-over-quarter to $2.18B.

Based on Avoro Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.